Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
Identifieur interne : 001100 ( Ncbi/Merge ); précédent : 001099; suivant : 001101Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
Auteurs : Michel Engeln [France] ; Stefania Fasano ; Serge H. Ahmed ; Martine Cador ; Veerle Baekelandt ; Erwan Bezard ; Pierre-Olivier FernagutSource :
- Annals of neurology [ 1531-8249 ] ; 2013.
English descriptors
- KwdEn :
- Adenoviridae (genetics), Adenoviridae (metabolism), Animals, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Conditioning, Operant (drug effects), Conditioning, Operant (physiology), Disease Models, Animal, Dopaminergic Neurons (drug effects), Dopaminergic Neurons (pathology), Food Preferences (drug effects), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Mutation (genetics), Parkinson Disease (drug therapy), Parkinson Disease (etiology), Parkinson Disease (genetics), Parkinson Disease (pathology), Rats, Rats, Wistar, Reward, Saccharin (administration & dosage), Substantia Nigra (pathology), Sweetening Agents (administration & dosage), Taste (drug effects), Transduction, Genetic, Tyrosine 3-Monooxygenase (metabolism), Ubiquitin (metabolism), alpha-Synuclein (genetics), alpha-Synuclein (toxicity).
- MESH :
- chemical , administration & dosage : Saccharin, Sweetening Agents.
- chemical , genetics : alpha-Synuclein.
- chemical , metabolism : Tyrosine 3-Monooxygenase, Ubiquitin.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- drug effects : Conditioning, Operant, Dopaminergic Neurons, Food Preferences, Taste.
- drug therapy : Parkinson Disease.
- etiology : Parkinson Disease.
- genetics : Adenoviridae, Mutation, Parkinson Disease.
- metabolism : Adenoviridae.
- pathology : Dopaminergic Neurons, Parkinson Disease, Substantia Nigra.
- physiology : Conditioning, Operant.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- chemical , toxicity : alpha-Synuclein.
- Animals, Disease Models, Animal, Humans, Male, Rats, Rats, Wistar, Reward, Transduction, Genetic.
Abstract
Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α-synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients.
DOI: 10.1002/ana.23881
PubMed: 23494678
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000711
- to stream PubMed, to step Curation: 000680
- to stream PubMed, to step Checkpoint: 000680
Links to Exploration step
pubmed:23494678Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.</title><author><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, University of Bordeaux, Bordeaux, France; Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, National Center for Scientific Research, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, University of Bordeaux, Bordeaux, France; Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, National Center for Scientific Research, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Fasano, Stefania" sort="Fasano, Stefania" uniqKey="Fasano S" first="Stefania" last="Fasano">Stefania Fasano</name></author><author><name sortKey="Ahmed, Serge H" sort="Ahmed, Serge H" uniqKey="Ahmed S" first="Serge H" last="Ahmed">Serge H. Ahmed</name></author><author><name sortKey="Cador, Martine" sort="Cador, Martine" uniqKey="Cador M" first="Martine" last="Cador">Martine Cador</name></author><author><name sortKey="Baekelandt, Veerle" sort="Baekelandt, Veerle" uniqKey="Baekelandt V" first="Veerle" last="Baekelandt">Veerle Baekelandt</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23494678</idno><idno type="pmid">23494678</idno><idno type="doi">10.1002/ana.23881</idno><idno type="wicri:Area/PubMed/Corpus">000711</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000711</idno><idno type="wicri:Area/PubMed/Curation">000680</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000680</idno><idno type="wicri:Area/PubMed/Checkpoint">000680</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000680</idno><idno type="wicri:Area/Ncbi/Merge">001100</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.</title><author><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name><affiliation wicri:level="3"><nlm:affiliation>Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, University of Bordeaux, Bordeaux, France; Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, National Center for Scientific Research, Bordeaux, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, University of Bordeaux, Bordeaux, France; Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, National Center for Scientific Research, Bordeaux</wicri:regionArea><placeName><region type="region">Nouvelle-Aquitaine</region><region type="old region">Aquitaine</region><settlement type="city">Bordeaux</settlement></placeName></affiliation></author><author><name sortKey="Fasano, Stefania" sort="Fasano, Stefania" uniqKey="Fasano S" first="Stefania" last="Fasano">Stefania Fasano</name></author><author><name sortKey="Ahmed, Serge H" sort="Ahmed, Serge H" uniqKey="Ahmed S" first="Serge H" last="Ahmed">Serge H. Ahmed</name></author><author><name sortKey="Cador, Martine" sort="Cador, Martine" uniqKey="Cador M" first="Martine" last="Cador">Martine Cador</name></author><author><name sortKey="Baekelandt, Veerle" sort="Baekelandt, Veerle" uniqKey="Baekelandt V" first="Veerle" last="Baekelandt">Veerle Baekelandt</name></author><author><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name></author><author><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name></author></analytic><series><title level="j">Annals of neurology</title><idno type="eISSN">1531-8249</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae (genetics)</term><term>Adenoviridae (metabolism)</term><term>Animals</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Conditioning, Operant (drug effects)</term><term>Conditioning, Operant (physiology)</term><term>Disease Models, Animal</term><term>Dopaminergic Neurons (drug effects)</term><term>Dopaminergic Neurons (pathology)</term><term>Food Preferences (drug effects)</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Mutation (genetics)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (etiology)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (pathology)</term><term>Rats</term><term>Rats, Wistar</term><term>Reward</term><term>Saccharin (administration & dosage)</term><term>Substantia Nigra (pathology)</term><term>Sweetening Agents (administration & dosage)</term><term>Taste (drug effects)</term><term>Transduction, Genetic</term><term>Tyrosine 3-Monooxygenase (metabolism)</term><term>Ubiquitin (metabolism)</term><term>alpha-Synuclein (genetics)</term><term>alpha-Synuclein (toxicity)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Saccharin</term><term>Sweetening Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term><term>Ubiquitin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Conditioning, Operant</term><term>Dopaminergic Neurons</term><term>Food Preferences</term><term>Taste</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Adenoviridae</term><term>Mutation</term><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Adenoviridae</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Dopaminergic Neurons</term><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Conditioning, Operant</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="toxicity" xml:lang="en"><term>alpha-Synuclein</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Disease Models, Animal</term><term>Humans</term><term>Male</term><term>Rats</term><term>Rats, Wistar</term><term>Reward</term><term>Transduction, Genetic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α-synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23494678</PMID><DateCreated><Year>2013</Year><Month>09</Month><Day>16</Day></DateCreated><DateCompleted><Year>2013</Year><Month>11</Month><Day>07</Day></DateCompleted><DateRevised><Year>2014</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>74</Volume><Issue>1</Issue><PubDate><Year>2013</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann. Neurol.</ISOAbbreviation></Journal><ArticleTitle>Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.</ArticleTitle><Pagination><MedlinePgn>140-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.23881</ELocationID><Abstract><AbstractText>Dopamine dysregulation syndrome shares some core behavioral features with psychostimulant addiction, suggesting that dopamine replacement therapy can acquire psychostimulantlike properties in some patients with Parkinson disease (PD). We here report strong experimental evidence supporting this hypothesis in an α-synuclein rat model of PD. Although levodopa had no effect in controls, it acquired 2 prominent psychostimulantlike properties in Parkinsonian rats: (1) it produced intense reward on its own and in parallel (2) decreased interest in other nondrug reward. These 2 effects may combine to explain the addictive use of levodopa after loss of midbrain dopamine neurons in some PD patients.</AbstractText><CopyrightInformation>Copyright © 2013 American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Engeln</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, University of Bordeaux, Bordeaux, France; Institute of Neurodegenerative Diseases, UMR 5293, F-33000 Bordeaux, France, National Center for Scientific Research, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fasano</LastName><ForeName>Stefania</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ahmed</LastName><ForeName>Serge H</ForeName><Initials>SH</Initials></Author><Author ValidYN="Y"><LastName>Cador</LastName><ForeName>Martine</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baekelandt</LastName><ForeName>Veerle</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bezard</LastName><ForeName>Erwan</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Fernagut</LastName><ForeName>Pierre-Olivier</ForeName><Initials>PO</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013549">Sweetening Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D025801">Ubiquitin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber><NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>FST467XS7D</RegistryNumber><NameOfSubstance UI="D012439">Saccharin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000256" MajorTopicYN="N">Adenoviridae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003216" MajorTopicYN="N">Conditioning, Operant</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059290" MajorTopicYN="N">Dopaminergic Neurons</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005518" MajorTopicYN="N">Food Preferences</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012439" MajorTopicYN="N">Saccharin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013549" MajorTopicYN="N">Sweetening Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013649" MajorTopicYN="N">Taste</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014161" MajorTopicYN="N">Transduction, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D025801" MajorTopicYN="N">Ubiquitin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>11</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>01</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>03</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23494678</ArticleId><ArticleId IdType="doi">10.1002/ana.23881</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>France</li></country><region><li>Aquitaine</li><li>Nouvelle-Aquitaine</li></region><settlement><li>Bordeaux</li></settlement></list><tree><noCountry><name sortKey="Ahmed, Serge H" sort="Ahmed, Serge H" uniqKey="Ahmed S" first="Serge H" last="Ahmed">Serge H. Ahmed</name><name sortKey="Baekelandt, Veerle" sort="Baekelandt, Veerle" uniqKey="Baekelandt V" first="Veerle" last="Baekelandt">Veerle Baekelandt</name><name sortKey="Bezard, Erwan" sort="Bezard, Erwan" uniqKey="Bezard E" first="Erwan" last="Bezard">Erwan Bezard</name><name sortKey="Cador, Martine" sort="Cador, Martine" uniqKey="Cador M" first="Martine" last="Cador">Martine Cador</name><name sortKey="Fasano, Stefania" sort="Fasano, Stefania" uniqKey="Fasano S" first="Stefania" last="Fasano">Stefania Fasano</name><name sortKey="Fernagut, Pierre Olivier" sort="Fernagut, Pierre Olivier" uniqKey="Fernagut P" first="Pierre-Olivier" last="Fernagut">Pierre-Olivier Fernagut</name></noCountry><country name="France"><region name="Nouvelle-Aquitaine"><name sortKey="Engeln, Michel" sort="Engeln, Michel" uniqKey="Engeln M" first="Michel" last="Engeln">Michel Engeln</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001100 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 001100 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:23494678
|texte= Levodopa gains psychostimulant-like properties after nigral dopaminergic loss.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:23494678" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonFranceV1
| This area was generated with Dilib version V0.6.29. |  |